Associate Director of Ocular Oncology
Attending Physician
Associate Professor of Ophthalmology (Clinical Scholar), Keck School of Medicine of USC
  • Summary
  • Publications
  • Research
  • Media
  • Locations

Jesse L. Berry, MD, received her undergraduate and medical degree from Harvard University in Massachusetts. Following her ophthalmology residency at the University of Southern California, she was the assistant chief of service at the Los Angeles County Medical Center. She then completed a fellowship in Ocular Oncology at Children’s Hospital Los Angeles under the mentorship of Drs. Jonathan Kim and A. Linn Murphree. Dr. Berry is the founder of WOO, Women in Ocular Oncology.

Clinical Interests

Retinoblastoma, Choroidal Melanoma, Ocular Oncology, Clinical Outcomes

Education

Medical School: 

Harvard Medical School, Boston, MA, Doctor of Medicine

Internship: 

Memorial Sloan Kettering Cancer Center, Transitional Intern, New York, NY

Residency: 

Doheny Eye Institute, University of Southern California Ophthalmology, Los Angeles, CA

Fellowship: 

Children’s Hospital Los Angeles, University of Southern California, Ocular Oncology and Oculoplastic Surgery, Los Angeles, CA

Accomplishments

Professional Memberships: 

American Academy of ophthalmology, 2009-present

Association for Research in Vision & Ophthalmology, 2009-present

International Society of Ocular Oncology, 2008-present

American Society of Cataract and Refractive Surgery, 2012-present

Women in Ophthalmology, 2012-present

California Association of Eye Physicians and Surgeons, 2011-present

Los Angeles Society of Ophthalmology, 2011-present

Society of Heed Fellows, 2013-present

Awards: 

Harvard College Scholarship: Elizabeth Cary Agassiz Scholar, 2000-2004

Malcolm Kinsberg Scholarship, 2000-2004; Kappa Alpha Theta Foundation Scholarship, 2002

David Rockefeller Center of Latin American Studies Grant, 2003

Nevil & Louise Ford Scholarship Fund, 2004-2008

Harvard Medical International Initiatives in Research Grant, 2005

Center for Eye Research and Education McCleary Grant, 2007

Doheny Eye Institute Medical Knowledge Award, 2011

Starr Schulman Fellowship, 2012

Department of Health Services Innovation Grant, 2012

Heed Ophthalmic Foundation Fellow, 2013-2014

Society of Heed Fellows, 2013

University of Southern California Excellence in Resident Teaching Award, 2013

University of Southern California Excellence in Resident Teaching Award, 2014

University of Southern California Excellence in Resident Teaching Award, 2018

Publications: 

Berry JL, Jubran R, Kim JW, Wong KE, Almarzouki H*, Lee TC, Murphree AL. Long term Outcomes of Group D Eyes in Bilateral Retinoblastoma Patients Treated with Chemoreduction and Low-dose IMRT Salvage. Pediatr Blood Cancer. 60(4):688-93, 2013. PMID#22997170

Berry JL, Kogachi K*, Aziz HA, McGovern K, Zolfaghari E*, Murphree AL, Jubran R, Kim JW. Risk of Metastasis and Orbital Recurrence in Advanced Retinoblastoma Eyes Treated with Systemic Chemoreduction versus Primary Enucleation. Pediatr Blood Cancer. 64(4), 2017. PMID#28221729 Co-initiated the project, executed data collection, primary composer of manuscript

Berry JL, Bechtold M*, Shah S*, Zolfaghari E*, Reid M, Jubran R, Kim JW. Not all seeds are created equal: Seed Classification is Predictive of Outcomes in Retinoblastoma. Ophthalmology. 124(12): 1817-25, 2017. PMID#28655537

Berry JL, Shah S*, Bechtold M*, Zolfaghari E*, Jubran R, Kim JW. Long-term Outcomes of Group D Retinoblastoma Eyes during the Intravitreal Melphalan Era. Pediatr Blood Cancer. 64(12), 2017. PMCID#28646513

Berry JL, Xu L, Murphree AL, Krishnan S, Stachelek K, Zolfoghari E*, McGovern K, Lee TC, Carlsson A, Kuhn P, Kim JK, Cobrinik D, Hicks J. Potential of Aqueous Humor as a Surrogate Biopsy for Retinoblastoma. JAMA Ophthalmol. 135(11): 1221-1230, 2017. PMID#29049475, PMCID#PMC5710399

Research Interests: 

Evaluation of the aqueous humor for tumor-derived genetic information and its application to prognosis and precision medicine for retinoblastoma patients. Investigating new methods of chemotherapy delivery for the treatment of Retinoblastoma. Evaluating treatment outcomes for Retinoblastoma eyes. This includes evaluation of treatment outcomes after systemic chemotherapy and the elucidation of factors present at diagnosis, which contribute to final visual outcome in eyes treated for retinoblastoma.

4650 Sunset Blvd
Mail Stop #88
Los Angeles, CA 90027
Phone: 323-361-2279Office